Skip to main content
SpringerLink
Log in

Incremental Cost-Effectiveness Ratio and Net Monetary Benefit: Promoting the Application of Value-Based Pricing to Medical Devices—A European Perspective

  • Global Perspectives: Letter to the Editor
  • Published:
Therapeutic Innovation & Regulatory Science Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Hwang TJ, Kesselheim AS, Sarpatwari A. Value-based pricing and state reform of prescription drug costs. JAMA. 2017;318:609–610.

    Article  Google Scholar 

  2. Hulshof JA. Sustainable health care systems: the role of therapeutic value and value based pricing. Value Health. 2014;17: A452.

    Article  CAS  Google Scholar 

  3. Raftery J. Value based pricing: Can it work? BMJ. 2013;347:f5941.

    Article  Google Scholar 

  4. Callea G, Armeni P, Marsilio M, Jommi C, Tarricone R. The impact of HTA and procurement practices on the selection and prices of medical devices. Soc Sci Med. 2017;174:89–95.

    Article  Google Scholar 

  5. Panteli D, Arickx F, Cleemput I, et al. Pharmaceutical regulation in 15 European countries review. Health Syst Transit. 2016;18:1–122.

    PubMed  Google Scholar 

  6. Bach PB. Indication-specific pricing for cancer drugs. JAMA. 2014;312:1629–30.

    Article  CAS  Google Scholar 

  7. Bach PB, Pearson SD. Payer and policy maker steps to support value-based pricing for drugs. JAMA. 2015;314:2503–2504.

    Article  CAS  Google Scholar 

  8. Hunink MG, Weinstein MC, Wittenberg E, Pliskin P, Glasziou MF, Drummond JBW. Decision Making in Health and Medicine. Cambridge: Cambridge University Press; 2014.

    Book  Google Scholar 

  9. Trippoli S. Incremental cost-effectiveness ratio and net monetary benefit: current use in pharmacoeconomics and future perspectives. Eur J Intern Med. 2017;43: e36.

    Article  Google Scholar 

  10. Messori A, Trippoli S. Presenting the results of a pharmacoeconomic study: incremental cost-effectiveness ratio vs net monetary benefit. Heart. 2017;103:1746. http://heart.bmj.com/cgi/content/full/heartjnl-2017-311816?ijkey=Y8z2bM9zbQ6ZLvp&keytype=ref

    Article  Google Scholar 

  11. Morris S, Patel NV, Dobson J, et al. International Carotid Stenting Study investigators. Cost-utility analysis of stenting versus endarterectomy in the International Carotid Stenting Study. Int J Stroke. 2016;11:446–453.

    Article  Google Scholar 

  12. Radcliff K, Lerner J, Yang C, Bernard T, Zigler JE. Seven-year cost-effectiveness of ProDisc-C total disc replacement: results from investigational device exemption and post-approval studies. J Neurosurg Spine. 2016;24:760–768.

    Article  Google Scholar 

  13. Dylst P, Vulto A, Simoens S. Tendering for outpatient prescription pharmaceuticals: what can be learned from current practices in Europe? Health Policy. 2011;101:146–152.

    Article  Google Scholar 

  14. Martens M, Carbonnelle N. Same rules, different methods: White Paper on the public procurement of medicinal products. Bird&Bird website. http://www.twobirds.com/∼/media/pdfs/white-papers/public-procurement-of-medicinal-products.pdf. Published October 29, 2014. Accessed 12 Feb 2018.

  15. Trippoli S. Procurement of medical devices based on cost-effectiveness data. Recenti Prog Med. 2017;108:374–378.

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. HTA Unit, ESTAR, University of Florence, Regional Health System, Via di San Salvi 12, 50100, Firenze, Italy

    Andrea Messori PharmD & Sabrina Trippoli PharmD

Authors
  1. Andrea Messori PharmD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Sabrina Trippoli PharmD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Andrea Messori PharmD.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Messori, A., Trippoli, S. Incremental Cost-Effectiveness Ratio and Net Monetary Benefit: Promoting the Application of Value-Based Pricing to Medical Devices—A European Perspective. Ther Innov Regul Sci 52, 755–756 (2018). https://doi.org/10.1177/2168479018769300

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1177/2168479018769300

Keywords

Search

Navigation